ArticleNature immunology2022
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation.
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 61 citations in OpenAlex.
- Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer.Nature communications · 2024Trial
- Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4Cell reports methods · 2026Article
- Tumor-targeted IL-10 synergizes with IL-2 to enhance antitumor immunity while minimizing immune-related adverse events.Nature communications · 2026Article
- Coordinated Immune Activation Following KRAS Inhibition in Syngeneic Models Reveals Molecular Pathways that Potentiate and Limit Antitumor Immunity.Cancer immunology research · 2026Article
- Phagocytosis of necroptotic cells optimizes type 1 conventional dendritic cells for induction of a cytotoxic T-cell response.Cell death and differentiation · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- A distinct antigen presentation pathway drives potent T cell immunity in lipid nanoparticle-based mRNA vaccines.Science advances · 2026Article
- Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.Cancer immunology research · 2026Article
- Review
- Actomyosin rings constrain CD40 mobility to organize the dendritic cell immunological synapse.Cell communication and signaling : CCS · 2026Article
- Stem-like PD-1Journal for immunotherapy of cancer · 2026Article
- Integrative bioinformatics and machine learning approaches identify novel diagnostic signatures for oxaliplatin-resistant colorectal cancer.International journal of colorectal disease · 2026Article
- Diabetes exacerbates destructive inflammation by activating the CD137L-CD137 axis in dendritic and IL-17+ T cells.The Journal of clinical investigation · 2026Article
- Article
- The differentiation and function of heterogeneous thymic dendritic cell subsets require signals provided by distinct thymocyte cell types.Nature immunology · 2026Article
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Dendritic Cell Organization and Function in Innate and Adaptive Immune Defense Within Lymph Nodes.Immunological reviews · 2026Review
- Distinct dendritic cell cytoskeletal programs dictate synapse architecture and CD8Frontiers in immunology · 2026Article
- CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8Cancer immunology, immunotherapy : CII · 2025Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 1 country.
Renee WuDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Ray A OharaDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-7897-3169
Suin JoDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Tian-Tian LiuDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-9377-9938
Stephen T FerrisDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-3340-2607
Feiya OuDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Sunkyung KimDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Derek J TheisenDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
David A AndersonDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Brian W WongDepartment of Surgery, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-8447-3064
Timothy GershonDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Robert D SchreiberDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Theresa L MurphyDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.
Kenneth M MurphyDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA. kmurphy@wustl.edu.ORCID http://orcid.org/0000-0002-3505-9630
Washington University in St. Louis · USUniversity of North Carolina at Chapel Hill · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MWU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1MTRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8MTRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCERT32CA009547 · NCI · WASHINGTON UNIVERSITY · PI ROBERT DAVID SCHREIBER · 1986 to 2026
$12.1MDifferentiation/migratory fate of monocyte-derived cellsR01AI049653 · NIAID · WASHINGTON UNIVERSITY · PI Gwendalyn J Randolph · 2000 to 2026
$4.6MMolecular Basis of cDC1 DevelopmentR01AI162643 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2022 to 2025
$2.8MFunction of Wdfy4 in cross-presentation and immunityR01AI150297 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2019 to 2023
$2.5MUnderstanding the Mechanisms of DC Licensing in CD8 T Cell PrimingR01CA248919 · NCI · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2021 to 2025
$2.3MDEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPYR01CA190700 · NCI · WASHINGTON UNIVERSITY · PI SCHREIBER, ROBERT DAVID · 2015 to 2019
$2.1MMechanism of c-MYC repression by IRF8 in myeloid lineagesR21AI164142 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2021 to 2022
$433kTranscriptional basis of embryonic macrophage developmentR21AI163421 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2022 to 2023
$430kThe role of type 1 dendritic cells in CD4 and CD8 T cell anti-tumor immunityF30CA247262 · NCI · WASHINGTON UNIVERSITY · PI WU, RENEE PAULA · 2021 to 2023
$117kNCI NIH HHS F30 CA247262NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA190700NCI NIH HHS R01 CA248919NCI NIH HHS T32 CA009547NIAID NIH HHS R01 AI049653NIAID NIH HHS R01 AI150297NIAID NIH HHS R01 AI162643NIAID NIH HHS R21 AI163421NIAID NIH HHS R21 AI164142NIAID NIH HHS T32 AI007163NIDDK NIH HHS P30 DK020579
Abstract
CD40 signaling in classical type 1 dendritic cells (cDC1s) is required for CD8 T cell-mediated tumor rejection, but the underlying mechanisms are incompletely understood. Here, we identified CD40-induced genes in cDC1s, including Cd70, Tnfsf9, Ptgs2 and Bcl2l1, and examined their contributions to anti-tumor immunity. cDC1-specific inactivation of CD70 and COX-2, and global CD27 inactivation, only partially impaired tumor rejection or tumor-specific CD8 T cell expansion. Loss of 4-1BB, alone or in Cd27
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAnimalsAntigen PresentationCD40 AntigensDendritic CellsMiceMice, Inbred C57BLCD40 Antigens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.